CLIMB BIO, INC. Operating Expenses
CLIMB BIO, INC. (CLYM) reported Operating Expenses of $15.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- CLIMB BIO, INC. operating expenses for the quarter ending 2026-06-30 was $15.36M, a 43.85% increase year-over-year.
- CLIMB BIO, INC. operating expenses for the quarter ending 2026-03-31 was $15.21M, a 33.92% decline year-over-year.
- CLIMB BIO, INC. operating expenses for the quarter ending 2025-12-31 was $19.30M, a 76.85% increase year-over-year.
- CLIMB BIO, INC. operating expenses for the quarter ending 2025-09-30 was $14.89M, a 26.93% increase year-over-year.
- CLIMB BIO, INC. operating expenses for fiscal 2025 was $67.88M, a 17.24% decline from fiscal 2024.
- CLIMB BIO, INC. operating expenses for fiscal 2024 was $82.02M, a 103.65% increase from fiscal 2023.
- CLIMB BIO, INC. operating expenses for fiscal 2023 was $40.27M, a 10.77% decline from fiscal 2022.
- CLIMB BIO, INC. operating expenses for fiscal 2022 was $45.13M, a 26.53% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.36M 10-Q · filed 2026-08-06 | $30.57M 10-Q · filed 2026-08-06 | $49.87M derived: sum of 3 quarters · filed 2026-08-06 | $64.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $15.21M 10-Q · filed 2026-05-07 | $34.51M derived: sum of 2 quarters · filed 2026-05-07 | $49.40M derived: sum of 3 quarters · filed 2026-05-07 | $60.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $19.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $34.19M derived: sum of 2 quarters · filed 2026-03-05 | $44.87M derived: sum of 3 quarters · filed 2026-08-06 | $67.88M 10-K · filed 2026-03-05 |
| 2025-09-30 | $14.89M 10-Q · filed 2025-11-06 | $25.57M derived: sum of 2 quarters · filed 2026-08-06 | $48.59M 10-Q · filed 2025-11-06 | $59.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $10.68M 10-Q · filed 2026-08-06 | $33.70M 10-Q · filed 2026-08-06 | $44.61M derived: sum of 3 quarters · filed 2026-08-06 | $56.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $23.02M 10-Q · filed 2026-05-07 | $33.93M derived: sum of 2 quarters · filed 2026-05-07 | $45.66M derived: sum of 3 quarters · filed 2026-05-07 | $102.03M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $10.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $22.64M derived: sum of 2 quarters · filed 2026-03-05 | $79.02M derived: sum of 3 quarters · filed 2026-03-05 | $82.02M 10-K · filed 2026-03-05 |
| 2024-09-30 | $11.73M 10-Q · filed 2025-11-06 | $68.10M derived: sum of 2 quarters · filed 2025-11-06 | $71.11M 10-Q · filed 2025-11-06 | $76.23M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $56.37M 10-Q · filed 2025-08-12 | $59.38M 10-Q · filed 2025-08-12 | $64.50M derived: sum of 3 quarters · filed 2025-08-12 | $69.50M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $3.00M 10-Q · filed 2025-05-14 | $8.13M derived: sum of 2 quarters · filed 2025-05-14 | $13.13M derived: sum of 3 quarters · filed 2025-05-14 | $19.84M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $5.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $10.12M derived: sum of 2 quarters · filed 2025-03-25 | $16.84M derived: sum of 3 quarters · filed 2025-03-25 | $40.27M 10-K · filed 2025-03-25 |
| 2023-09-30 | $5.00M 10-Q · filed 2024-11-12 | $11.71M derived: sum of 2 quarters · filed 2024-11-12 | $35.15M 10-Q · filed 2024-11-12 | $44.71M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $6.71M 10-Q · filed 2024-08-14 | $30.15M 10-Q · filed 2024-08-14 | $39.71M derived: sum of 3 quarters · filed 2024-08-14 | $48.45M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $23.44M 10-Q · filed 2024-05-15 | $32.99M derived: sum of 2 quarters · filed 2024-05-15 | $41.74M derived: sum of 3 quarters · filed 2024-05-15 | $55.44M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $9.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $18.30M derived: sum of 2 quarters · filed 2024-03-28 | $32.00M derived: sum of 3 quarters · filed 2024-03-28 | $45.13M 10-K · filed 2024-03-28 |
| 2022-09-30 | $8.75M 10-Q · filed 2023-11-14 | $22.45M derived: sum of 2 quarters · filed 2023-11-14 | $35.58M 10-Q · filed 2023-11-14 | $46.28M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $13.70M 10-Q · filed 2023-08-10 | $26.83M 10-Q · filed 2023-08-10 | $37.54M derived: sum of 3 quarters · filed 2023-08-10 | $46.92M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $13.13M 10-Q · filed 2023-05-11 | $23.84M derived: sum of 2 quarters · filed 2023-05-11 | $33.22M derived: sum of 3 quarters · filed 2023-05-11 | $41.92M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $10.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $20.09M derived: sum of 2 quarters · filed 2023-03-06 | $28.79M derived: sum of 3 quarters · filed 2023-03-06 | $35.67M 10-K · filed 2023-03-06 |
| 2021-09-30 | $9.38M 10-Q · filed 2022-11-14 | $18.09M derived: sum of 2 quarters · filed 2022-11-14 | $24.97M 10-Q · filed 2022-11-14 | $40.08M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $8.71M 10-Q · filed 2022-08-15 | $15.59M 10-Q · filed 2022-08-15 | $30.69M derived: sum of 3 quarters · filed 2022-08-15 | $32.95M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $6.88M 10-Q · filed 2022-05-16 | $21.99M derived: sum of 2 quarters · filed 2022-05-16 | $24.25M derived: sum of 3 quarters · filed 2022-05-16 | $25.85M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $15.11M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $17.37M derived: sum of 2 quarters · filed 2022-03-07 | $18.97M derived: sum of 3 quarters · filed 2022-03-07 | $20.93M 10-K · filed 2022-03-07 |
| 2020-09-30 | $2.26M 10-Q · filed 2021-11-08 | $3.87M derived: sum of 2 quarters · filed 2021-11-08 | $5.82M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $1.61M 10-Q · filed 2021-09-13 | $3.56M 10-Q · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |